Moderna’s (MRNA) experimental mRNA-based flu vaccine will be reviewed by an FDA advisory panel on June 18 ahead of an August 5 approval decision, signaling a possible return to greater transparency in the agency’s review process after advisory hearings became less common during the second Trump administration, Bloomberg’s Rachel Cohrs Zhang and Gerry Smith report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Mixed options sentiment in Moderna with shares down 3.48%
- Moderna Stock Stumbles as Vaccine Hype Meets Reality
- Davis to become acting director of CDER after Hoeg exit, Bloomberg says
- Moderna and Merck Push Personalized Lung Cancer Vaccine Into Phase 3
- SPDR S&P 500 ETF Trust (SPY) Daily Update, 5/13/2026